Specialist pharma Amzell B.V. signs agreement with Amring Pharmaceuticals Inc.to develop and commercialize clinical-stage candidate

Specialist pharma Amzell B.V. signs agreement with Amring Pharmaceuticals Inc.to develop and commercialize clinical-stage candidate

Leading specialist development pharma, Amzell B.V, has signed a license and development agreement with Amring Pharmaceuticals Inc., a subsidiary of SEVER Life Sciences B.V., for the commercial rights to one of its leading clinical-stage candidates. Under the agreement, Amzell will complete the full clinical development of the product, and Amring will take on the commercialization. Amring will also be investing an undisclosed amount into the product’s clinical development and the FDA approval process.

Dario Carrara, PhD., Amzell’s CEO said, “We are very excited to be working with Amring to bring this product to the market and into extensive clinical use where it can meet critical patient needs. This program is one of our top priorities. We are moving rapidly into the advanced phase of our clinical trial program.”

Daniel Carbery, President and CEO of Amring, commented, “With the completion of this agreement and the acquisition of broad commercial rights, Amring is rapidly expanding its position as an important leader in bringing critical and affordable treatments for patients. This agreement will significantly expand our commercial presence in the USA and several regions globally. We believe that this brings long term value to patients and customers in our target markets.”

Amzell specializes in developing well-characterized active substances utilizing its innovative drug delivery technology platforms. Its innovative platform drug delivery technologies provide effective drug delivery, increased efficacy, and improved safety and compliance. Amzell currently has a number of novel candidates in clinical development, and recently acquired a high-end clinical laboratory facility based in Allschwil, Switzerland, to help to accelerate its growing development pipeline.